Target intelligence / Profile preview

P-fimbria (Pap pilus) (Pap)

Target
Pap
Molecular classification
Bacterial adhesin, Surface protein, Lectin
01

Overview

P-fimbriae, also known as pyelonephritis-associated pili (Pap), are hair-like surface appendages expressed by uropathogenic Escherichia coli (UPEC) that are critical for the colonization of the upper urinary tract (Roberts et al., 1994). These structures are essential virulence factors that facilitate the colonization of the upper urinary tract by binding specifically to Gal(alpha1-4)Gal-containing glycolipids on renal epithelial cells (Dodson et al., 2001). The binding is primarily mediated by the PapG adhesin, a protein located at the distal tip of the fimbria. Because P-fimbriae are crucial for the transition from bladder infection (cystitis) to kidney infection (pyelonephritis), they are significant targets for anti-adhesion therapies. Therapeutic approaches include the use of galabioside analogs to competitively inhibit binding and pilicides that disrupt the chaperone-usher pathway required for pilus assembly (Pinkner et al., 2006). Additionally, cranberry-derived proanthocyanidins have been shown to inhibit the adhesion of P-fimbriated E. coli to uroepithelial cells (Howell et al., 2005). Targeting these fimbriae offers a potential alternative to traditional antibiotics, which may help in reducing the emergence of antimicrobial resistance by disarming the pathogen's ability to colonize rather than killing the bacteria directly.

Other names
Pyelonephritis-associated piliPap piliGal-Gal piliP-fimbriated Escherichia coli adhesinPapG adhesin
02

Mechanism of action

Competitive inhibition of PapG adhesin binding to host Gal(alpha1-4)Gal receptors and disruption of pilus biogenesis via the chaperone-usher pathway.

03

Biological functions

Bacterial adhesionColonizationPathogenesis
04

Disease associations

Urinary tract infectionPyelonephritisBacteremia
05

Safety considerations

Specificity for pathogenic vs commensal strainsLow oral bioavailability of carbohydrate-based inhibitorsPotential off-target effects on host carbohydrate-binding proteins
06

Interacting drugs

Cranberry proanthocyanidins

2 more in the full profile.

07

Biomarkers

Presence of papG geneP-blood group antigen status

Beyond the preview

Go deeper on P-fimbria (Pap pilus) (Pap).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-fimbria (Pap pilus) (Pap).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call